Biological therapy utilization, switching, and cost among patients with psoriasis: retrospective analysis of administrative databases in Southern Italy

Guerriero, Francesca; Orlando, Valentina; Monetti, Valeria Marina; Russo, Veronica; Menditto, Enrica

doi:10.2147/ceor.s147558

Cited by 26 publications

(20 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the retrospective observational study conducted by Guerriero et al estimated, using data from an administrative database of a South Italian Local Healthcare Unit (ASL, Azienda Sanitaria Locale), an average annual cost per patient treated with a biologic of € 10,536. If- with regard to the data collected by us-we considered only the direct healthcare costs for patients receiving a biologic, under the hypothesis of being able to extrapolate them to one year, we would get an average cost per patient treated equal to € 11,222, in line with what estimated by Guerriero et al [18].…”

Section: 4%; P=00233)supporting

confidence: 73%

The Cost of Psoriasis in Patients under Conventional Systemic Therapy or Biologic: The Results of a Retrospective Analysis Carried out in an Italian Center

Ravasio¹,

Rostagno²,

Zagni³

et al. 2018

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

Objective: To present an update of the cost profile of psoriasis in patients with conventional systemic therapy or biologic referring to a Center of the Piedmont Region. Methods: A retrospective, observational cohort study was conducted to estimate the cost of the treatment with conventional systemic therapy or biologic of adult patients with psoriasis referring to an Italian Center. The enrollment window started on July 1, 2017 and ended on January 31, 2018. Each patient identified was followed-up retrospectively for six months. The database collected the main details on demographics, clinical data and resource consumption (treatments administered, visits, blood tests and instrumental examinations, etc.) for each patient enrolled. The PASI index was evaluated to reconstruct the evolution over time of the seriousness of psoriasis for each patient enrolled. Results: 181 patients were considered, 45.9% treated with a biologic and 54.1% with a conventional systemic therapy. During the 6 months follow-up, 2.4% patients with biologic and 11.2% with conventional systemic therapy discontinued the treatment (p=0.0233). At the beginning (baseline) a more compromised disease activity (PASI score) in patients with the biologic emerged (19.8 vs. 13.9; p=0.0005). Twelve months before enrolment the average PASI score showed a substantial overlap (5.9 vs. 5.8; p=0.9375). Upon enrollment patients treated with the biologic reported the lowest mean PASI score (2.7 vs. 3.8; p=0.1127). The 6 months cost of treatment was € 5,675 for biologic and € 321 for conventional systemic therapy (p<0.0001). The cost for the management of psoriasis was significantly higher in patients with moderate-to-severe PASI. Conclusions: The data collected seem to be sufficient to state that psoriasis is a disease with a quite high overall cost for the NHS and/or society, and that, due to its chronicity, such cost is likely to increase with the progression of severity.

show abstract

Section: 4%; P=00233)supporting

confidence: 73%

The Cost of Psoriasis in Patients under Conventional Systemic Therapy or Biologic: The Results of a Retrospective Analysis Carried out in an Italian Center

Ravasio¹,

Rostagno²,

Zagni³

et al. 2018

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

show abstract

“…The above databases had been previously validated and used to produce drug-utilization information. [20][21][22][23][24][25] Data sources were matched by record linkage analysis through a unique and anonymous personal identification code. Such code was created by a database manager uninvolved in the data analysis, preventing patient identification.…”

Section: Data Sourcementioning

confidence: 99%

<p>Drug Utilization Pattern of Antibiotics: The Role of Age, Sex and Municipalities in Determining Variation</p>

Orlando

Monetti

Juste

et al. 2020

RMHP

Self Cite

View full text Add to dashboard Cite

Purpose: The purpose was to analyze drug prescription and antibiotic use by age and sex in Italy's Campania Region, and to estimate the distribution of prescription rates in children (≤14 years old), adults (between 15 and 65 years old), and older adults (≥65 years old) at a municipality level. Methods: This was a retrospective analysis of pharmacy records in Campania (Southern Italy), in 2016. Difference in antibiotic prescriptions in different age groups was assessed by prevalence rates. Age-adjusted prevalence rates were categorized into quintiles and mapped by the patient's municipality of residence. Relationship between prevalence rates for the different age groups was estimated using the non-parametric Spearman rank correlation test. Results: There were 2,738,118 were patients with at least one antibiotic prescription. Antibiotics prescription was higher in children aged <5 years and in the older adults aged >70 years. Prevalence rate distribution was different among municipalities in all age groups. A positive correlation between the rank distribution of prevalence rates at municipality level was identified for children and adults (rs=0.56; P<0.01), adults and the older adults (rs=0.79; P<0.01), and children and the older adults (rs=0.46; P<0.01). Among the studied age groups, the most prescribed antibiotic class was penicillin (except the older adults aged ≥85 years) ranging from 45% in children to 27.2% in the older adults. Fluoroquinolones were the least prescribed antibiotic class, ranging from 0.2% in children to 30.2% in the older adults. Conclusion: A considerably high use of antibiotic drugs has been detected in Campania Region, with values exceeding the regional and national average. Prescriptions at municipal level differ from one age group to another. Antibiotic use is often unjustified, and to decrease the number of prescriptions and improve their appropriateness, several measures at territorial level are recommended.

show abstract

“…The Campania Region Database (CaReDB) includes information on patient demographics, the electronic records of outpatient pharmacy dispensing and hospital discharges for ~6 million residents of a well-defined population in Italy (~10% of the population of Italy). CaReDB is complete and includes validated data in previous drug utilization studies [9][10][11][12][13][14][15][16][17]. The characteristics of CaReDB are described in S1 Table. From the beginning of the Covid-19 epidemic, a surveillance system was implemented to collect all cases identified by reverse transcription-polymerase chain reaction (RT-PCR) testing for SARS-CoV-2.…”

Section: Target Population and Data Sourcementioning

confidence: 99%

Development and validation of a clinical risk score to predict the risk of SARS-CoV-2 infection from administrative data: a population-based cohort study from Italy

Orlando

Rea

Savaré

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundThe novel coronavirus (SARS-CoV-2) pandemic spread rapidly worldwide increasing exponentially in Italy. To date, there is lack of studies describing clinical characteristics of the population most at risk of infection. Hence, we aimed to identify clinical predictors of SARS-CoV-2 infection risk and to develop and validate a score predicting SARS-CoV-2 infection risk comparing it with unspecific surrogates.MethodsRetrospective case/control study using administrative health-related database was carried out in Southern Italy (Campania region) among beneficiaries of Regional Health Service aged over than 30 years. For each subject with Covid-19 confirmed diagnosis (case), up to five controls were randomly matched for gender, age and municipality of residence. Odds ratios and 90% confidence intervals for associations between candidate predictors and risk of infection were estimated by means of conditional logistic regression. SARS-CoV-2 Infection Score (SIS), was developed by generating a total aggregate score obtained from assignment of a weight at each selected covariate using coefficients estimated from the model. Finally, the score was categorized by assigning increasing values from 1 to 4. SIS was validated by comparison with specific and unspecific predictors of SARS-CoV-2 infection.ResultsSubjects suffering from diabetes, anaemias, Parkinson’s disease, mental disorders, cardiovascular and inflammatory bowel and kidney diseases showed increased risk of SARS-CoV-2 infection. Similar estimates were recorded for men and women and younger and older than 65 years. Fifteen conditions significantly contributed to the SIS. As SIS value increases, risk progressively increases, being odds of SARS-CoV-2 infection among people with the highest SIS value (SIS=4), 1.74 times higher than those unaffected by any SIS contributing conditions (SIS=1).ConclusionThis study identified conditions and diseases making individuals more vulnerable to SARS-CoV-2 infection. Our results are a decision-maker support tool for identifying population most at risk allowing adoption of preventive measures to minimize a potential new relapse damage.

show abstract

Biological therapy utilization, switching, and cost among patients with psoriasis: retrospective analysis of administrative databases in Southern Italy

Cited by 26 publications

References 16 publications

The Cost of Psoriasis in Patients under Conventional Systemic Therapy or Biologic: The Results of a Retrospective Analysis Carried out in an Italian Center

The Cost of Psoriasis in Patients under Conventional Systemic Therapy or Biologic: The Results of a Retrospective Analysis Carried out in an Italian Center

<p>Drug Utilization Pattern of Antibiotics: The Role of Age, Sex and Municipalities in Determining Variation</p>

Development and validation of a clinical risk score to predict the risk of SARS-CoV-2 infection from administrative data: a population-based cohort study from Italy

Contact Info

Product

Resources

About